FDA doesn’t OK nasal spray EpiPen alternative; Raleigh firm also has one under development

RALEIGH – Federal regulators declined to approve a nasal spray to treat severe allergic reactions late Tuesday, calling for more research on what would have been the first alternative to injections using devices such as an EpiPen.

The device is from ARS Pharmaceuticals based in San Diego.

A Raleigh-based firm, Bryrn Pharma, also has an EpiPen alternative in the works. The company has raised millions of dollars from nearly 200 investors to fund its efforts. It recently hired a new CEO to spearhead submission of a new drug application, or NDA, for FDA consideration.

The U.S. Food and Drug Administration told ARS that the company needs to conduct another study on repeat doses of epinephrine, a drug that halts potentially life-threating reactions, called anaphylaxis, using the company’s nasal spray device compared with injections.

The move comes four months after an FDA advisory committee recommended approval of the device, dubbed neffy. The FDA is not required to follow the committee’s recommendations, though it usually does.

Raleigh’s Bryn Pharma – developing alternative to needles to fight deadly allergies- raises $11M

Raleigh-based Bryn Pharma brings on new CEO to help launch EpiPen alternative

Bryn is best known for its investigational epinephrine nasal spray, UTULY.

Richard Lowenthal, president and chief executive of ARS, said in a statement that the company would appeal the FDA’s decision and resubmit an application in early 2024.

The ARS product is one of several needle-free devices being developed to treat dangerous reactions to food, insect stings and medications. Such a device could alter treatment for the between 33 million and 45 million Americans with severe allergies to food and other triggers.

Advocates for people with allergies said they were “frustrated” by the FDA’s request for more research.

“Our community believe this innovation would finally come to the more than 10% of Americans with life-threatening food allergies, but instead, the FDA will force us to wait even longer,” Sung Poblete, chief executive of Food Allergy Research & Education, a nonprofit group, said in a statement.

Nearly 170 investors pour $28M into Raleigh startup focusing on counter to deadly allergic reactions

The post FDA doesn’t OK nasal spray EpiPen alternative; Raleigh firm also has one under development first appeared on WRAL TechWire.

fda
research
fund
pharmaceuticals
pharma